Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MATINAS BIOPHARMA HOLDINGS, INC.

(MTNB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MATINAS BIOPHARMA HOLDINGS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)

09/20/2021 | 07:07am EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.



(b) On September 17, 2021, director Patrick LePore informed the Board of Directors (the "Board") of Matinas BioPharma Holdings, Inc. (the "Company") that he will not stand for re-election to the Board at the upcoming annual meeting of stockholders, which will be held on November 1, 2021 (the "Annual Meeting"). Mr. LePore's term as a member of the Board will expire at the Annual Meeting.

Item 7.01 Regulation FD Disclosure.

The Company issued a press release announcing the nomination of Kathryn Penkus Corzo to stand for election to the Board at the Annual Meeting, and that Mr. LePore will not stand for re-election at the Annual Meeting. A copy of the press release discussing these matters is filed as Exhibit 99.1 to, and incorporated by reference in, this report.

The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 8.01. Other Events.




On September 13, 2021, the Company announced the nomination of Ms. Corzo to stand for election to the Board at the Annual Meeting. Ms. Corzo is currently a partner at Takeda Ventures, Inc. and was previously Head, Oncology Cell Therapy Development at Takeda Pharmaceuticals Company Limited. The Company also announced that Mr. LePore will not stand for re-election to the Board at the Annual Meeting.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibits are being furnished with this report:



Exhibit No.   Description

99.1            Press Release, dated September 20, 2021.

104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)




-2-

© Edgar Online, source Glimpses

All news about MATINAS BIOPHARMA HOLDINGS, INC.
11/18Matinas BioPharma to Participate in 33rd Annual Piper Sandler Virtual Healthcare Confer..
AQ
11/08Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highligh..
PU
11/08Note 2 - Liquidity and Plan of Operations
AQ
11/08Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Third Quarter and Nin..
CI
11/08Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highligh..
AQ
11/02Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2021 Financial an..
GL
11/01MATINAS BIOPHARMA HOLDINGS, INC. : Submission of Matters to a Vote of Security Holders (fo..
AQ
11/01Matinas BioPharma Holdings, Inc. Elects Kathryn Corzo to the Board of Directors
CI
10/25MATINAS BIOPHARMA : Selected to Participate in the B. Riley Fall 2021 Growth Biotech Best ..
AQ
10/21MATINAS BIOPHARMA : Doses First Patient in Phase 1 Study of Antibiotic Drug Candidate
MT
More news
Analyst Recommendations on MATINAS BIOPHARMA HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 0,47 M - -
Net income 2021 -23,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -9,28x
Yield 2021 -
Capitalization 236 M 236 M -
Capi. / Sales 2021 499x
Capi. / Sales 2022 59,1x
Nbr of Employees 20
Free-Float 96,0%
Chart MATINAS BIOPHARMA HOLDINGS, INC.
Duration : Period :
Matinas BioPharma Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,09 $
Average target price 2,75 $
Spread / Average Target 152%
EPS Revisions
Managers and Directors
Jerome D. Jabbour President, Chief Executive Officer & Director
Keith A. Kucinski Chief Financial Officer
Herbert J. Conrad Chairman
Raphael J. Mannino Chief Scientific Officer & Senior Vice President
James J. Ferguson Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MATINAS BIOPHARMA HOLDINGS, INC.-19.85%236
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.39%24 431